Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of empagliflozin + metformin versus Jardiance Duo under fed conditions in healthy Thai adults
TCTR20260908005Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + metformin, empagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Empagliflozin plasma concentration-time profile, Metformin plasma concentration-time profile and 3 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
empagliflozin + metforminempagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20260908005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260908005.